Fig. 1From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutationsPatient disposition. (AE: adverse event)Back to article page